Short answer
Korro Bio, Inc. (KRRO) filed an 8-K current report with the SEC on October 5, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). First ANCHOR cohort dosed, advancing KRRO-121 into Phase 1/2 clinical testing.
Korro Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- First ANCHOR cohort dosed, advancing KRRO-121 into Phase 1/2 clinical testing
- KRRO-121 targets hyperammonemia in urea cycle disorders and hepatic encephalopathy
- Clinical progress creates a potential catalyst, with future readouts driving efficacy and safety assessment
- Exhibit 99.1 contains the company’s supporting press release
Item EX-99.1 · Exhibit EX-99.1
- First cohort dosed in Phase 1/2 ANCHOR trial, advancing KRRO-121 from preclinical testing into human safety evaluation
- Single 2mg/kg dose administered to healthy volunteers, with placebo-controlled SAD and MAD studies planned for up to 50 participants
- UCD patient dosing expected in first half of 2027, with interim clinical readout expected in second half of 2027
- Phase 2 plans up to 15 UCD participants across all genotypes, supporting KRRO-121’s potential pan-UCD positioning
- Clinical validation now becomes the key catalyst, with safety, pharmacokinetics and ammonia-control activity determining program value
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Korro Bio, Inc. 8-K filings
Get the next KRRO 8-K as it lands
Follow KRRO for push alerts, or ask the research agent what this filing means.